Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBS – Research Report), Inovio Pharmaceuticals (INO – Research Report) and Assembly Biosciences (ASMB – Research Report).
Emergent Biosolutions (EBS)
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions today and set a price target of $55.00. The company’s shares closed last Tuesday at $19.73, close to its 52-week low of $18.00.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of
Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $40.00.
See the top stocks recommended by analysts >>
Inovio Pharmaceuticals (INO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals. The company’s shares closed last Tuesday at $2.14, close to its 52-week low of $1.38.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Inovio Pharmaceuticals is a Hold with an average price target of $3.33, a 53.5% upside from current levels. In a report issued on October 27, RBC Capital also maintained a Hold rating on the stock with a $3.00 price target.
Assembly Biosciences (ASMB)
In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences, with a price target of $2.50. The company’s shares closed last Tuesday at $1.37, close to its 52-week low of $1.32.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Currently, the analyst consensus on Assembly Biosciences is a Moderate Buy with an average price target of $6.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EBS: